236 related articles for article (PubMed ID: 16965507)
1. Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization.
Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2006 Oct; 84(5):707-8. PubMed ID: 16965507
[No Abstract] [Full Text] [Related]
2. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
Spandau UH; Jonas JB
Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
[No Abstract] [Full Text] [Related]
3. Pneumatic displacement and intravitreal bevacizumab in the management of subretinal haemorrhage caused by choroidal neovascularization.
Hasler PW; la Cour M; Villumsen J
Acta Ophthalmol Scand; 2007 Aug; 85(5):577-9. PubMed ID: 17559558
[No Abstract] [Full Text] [Related]
4. Intravitreal bevacizumab injection for peripheral exudative hemorrhagic chorioretinopathy.
Alforja MS; Sabater N; Giralt J; Adán A; Pelegrín L; Casaroli-Marano R
Jpn J Ophthalmol; 2011 Jul; 55(4):425-427. PubMed ID: 21633808
[No Abstract] [Full Text] [Related]
5. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.
Laud K; Spaide RF; Freund KB; Slakter J; Klancnik JM
Retina; 2006 Oct; 26(8):960-3. PubMed ID: 17031300
[No Abstract] [Full Text] [Related]
6. The use of intravitreal bevacizumab to treat choroidal neovascular membranes (CNVMs).
Derriman L; Marshall J; Moorman C; Downes SM
Retina; 2008 Jun; 28(6):910; author reply 910-1. PubMed ID: 18536613
[No Abstract] [Full Text] [Related]
7. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
Bom Aggio F; Eid Farah M; Melo GB
Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
[No Abstract] [Full Text] [Related]
8. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation.
Engelbert M; Zweifel SA; Freund KB
Retina; 2009; 29(10):1424-31. PubMed ID: 19898180
[TBL] [Abstract][Full Text] [Related]
9. Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks.
Teixeira A; Moraes N; Farah ME; Bonomo PP
Acta Ophthalmol Scand; 2006 Dec; 84(6):835-6. PubMed ID: 17083556
[No Abstract] [Full Text] [Related]
10. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia.
Tewari A; Dhalla MS; Apte RS
Retina; 2006; 26(9):1093-4. PubMed ID: 17151505
[No Abstract] [Full Text] [Related]
11. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
Ehrlich R; Ciulla TA; Maturi R; Kheradiya NS; Hrisomalos N; Shulman S; Guess MG; Coyle E; Harris A
Retina; 2009; 29(10):1418-23. PubMed ID: 19898179
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma.
Song JH; Bae JH; Rho MI; Lee SC
Retina; 2010 Jun; 30(6):945-51. PubMed ID: 20531145
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for choroidal neovascularization related to inflammatory diseases.
Kramer M; Axer-Siegel R; Jaouni T; Reich E; Hemo I; Priel E; Averbukh E; Ehrlich R; Chowers I; Weinberger D; Amer R
Retina; 2010 Jun; 30(6):938-44. PubMed ID: 20168273
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration.
Chen E; Kaiser RS; Vander JF
Retina; 2007; 27(4):445-50. PubMed ID: 17420696
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab in inflammatory ocular neovascularization.
Mansour AM; Mackensen F; Arevalo JF; Ziemssen F; Mahendradas P; Mehio-Sibai A; Hrisomalos N; Lai TY; Dodwell D; Chan WM; Ness T; Banker AS; Pai SA; Berrocal MH; Tohme R; Heiligenhaus A; Bashshur ZF; Khairallah M; Salem KM; Hrisomalos FN; Wood MH; Heriot W; Adan A; Kumar A; Lim L; Hall A; Becker M
Am J Ophthalmol; 2008 Sep; 146(3):410-416. PubMed ID: 18619571
[TBL] [Abstract][Full Text] [Related]
17. Photoreceptor reconstitution correlates with visual improvement after intravitreal bevacizumab treatment of choroidal neovascularization secondary to traumatic choroidal rupture.
Francis JH; Freund KB
Retina; 2011 Feb; 31(2):422-4. PubMed ID: 21240036
[No Abstract] [Full Text] [Related]
18. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
